Search - tctmd.com

Displaying 761 - 780 of 899

Sort: Relevancy | Date

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

Caitlin E. Cox

September 14, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Daily News

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

Yael L. Maxwell

August 31, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Presentation ESC 2017

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

Presenter: John Eikelboom

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Lower Blood Pressure May Protect Against Cognitive Decline in Adults in Their 70s

Todd Neale

August 22, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

Advertisement

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Hormone Therapy Doesn’t Impact Long-term All-Cause, CV, or Cancer Mortality: WHI Analysis

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Popular CV Risk Calculator Is Not Accurate Among Patients at Low Socioeconomic Standing

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Rivaroxaban With or Without Aspirin in Stable Cardiovascular Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Evolocumab Not Cost-Effective at Current List Price

Lower Blood Pressure May Protect Against Cognitive Decline in Adults in Their 70s

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content